. 2008 Feb 21;99(4):799–804. doi: 10.1111/j.1349-7006.2008.00727.x

Table 2.

Summary of mutations in imatinib‐resistant GIST

No.	Timing	Radiological appearance	Viable tumor cells	KIT	Primary mutation		Secondary mutation		Allelic location
1		Enlargement	+	+	ex11 ^†	del 554–570	ex13	V654A	cis
2		Nodule in a mass	+	+	ex11 ^†	del 557–558	ex13	V654A
3		Enlargement	+	+	ex11 ^†	del 557–558	ex13	V654A
4	Metachronous	Enlargement	+	+	ex11 ^†	del 556–557	ex13	V654A	cis
4	Metachronous	Enlargement	+	+			ex13	V654A
5	Synchronous	Enlargement	+	+	ex11	del 557–561	ex13	V654A
5	Synchronous	New lesion	+	+			ex13	V654A
6		Enlargement	+	+	ex11 ^†	del 552–572	ex13	V654A
7		Enlargement	+	+	ex11^†	del 552–572	ex13	V654A
8	Metachronous	Nodule in a mass	+	+	ex11	V560D	ex13	V654A	cis
	Metachronous	Nodule in a mass	+	+			Absent
	Metachronous	Nodule in a mass	+	+			Absent
9	Metachronous	Nodule in a mass	+	+	ex11 ^†	del 557–558	ex14	T670I	cis
	Metachronous	Nodule in a mass	+	+			ex14	T670I
	Metachronous	New lesion	+	+			ex14	T670I
10		Enlargement	+	+	ex11 ^†	del 557 + 558	ex16 + ex17	K786N + D816H	all cis
11		Enlargement	+	+	ex11	del 560	ex17	N822K	cis
12	Synchronous	Nodule in a mass	+	+	ex11 ^†	del 555–572	ex17	N822K	cis
12	Synchronous	Nodule in a mass	+	+			ex17	N822Y	cis
13		Nodule in a mass	+	+	ex11 ^†	P551I and del 552–559	ex17	Y823D
14	Metachronous	Enlargement	+	+	ex9 ^†	dup 502 + 503	ex17	C809G
	Metachronous	Enlargement	+	+			ex17	N822K
	Metachronous	Enlargement	+	+			ex17	D816E
	Metachronous	New lesion	+	+			ex17	N822K	cis
15		Nodule in a mass	+	+	ex11 ^†	del 560–572	ex17	A829P
16		Nodule in a mass	+	+	ex11 ^†	del 557–558	ex17	D816H	cis
17	Metachronous	Nodule in a mass	+	+	ex11 ^†	del 557–558	ex17	Y823D	cis
17	Metachronous	Nodule in a mass	+	+			n.e.	n.e.
18	Synchronous	Enlargement	+	+	ex11 ^†	del 557–558	ex13	V654A	cis
	Synchronous	Enlargement	+	+			ex17	D816E, D820V	each cis
	Metachronous	Enlargement	+	+			ex13	V654A	cis
	Metachronous	Enlargement	+	+			ex13	Y823D	cis
19	Synchronous	Enlargement	+	+	ex11 ^†	del 559–574	ex17	V654A	cis
19	Synchronous	Enlargement	+	+			ex13	N822K	cis
20	Synchronous	Enlargement	+	+	ex11 ^†	del 557–561	ex13	V654A
20	Synchronous	Enlargement	+	+			ex17	N822D
21	Synchronous	Enlargement	+	+	ex11 ^†	K558N del 559	Absent
21	Synchronous	Enlargement	+	+			Absent
22	Synchronous	Nodule in a mass	+	+	ex11	V558S, V559S	Absent
22	Synchronous	Nodule in a mass	+	+			Absent
23		Nodule in a mass	+	+	ex9 ^†	dup 502 + 503	Absent
24	Synchronous	Enlargement	+	+	ex11 ^†	del 570–578	Absent
	Synchronous	Enlargement	+	+			Absent
	Metachronous	Enlargement	+	+			Absent
25		Enlargement	+	+	ex9 ^†	dup 502 +503	Absent

^{^†}

Primary mutation was confirmed using genomic DNA extracted from formalin‐fixed, paraffin‐embedded sections. +, positive; del, deletion; dup, duplication; ex, exon; n.e., not examined.